Trial Profile
A Randomised, Double-Blind, Placebo Controlled, Multi-Centre Phase II Study of Atacicept in Anti-TNF-alpha-naive Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jan 2022
Price :
$35
*
At a glance
- Drugs Atacicept (Primary) ; Adalimumab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms AUGUST II
- Sponsors EMD Serono; Merck Serono
- 21 Jan 2022 This trial has been completed in Finland, according to European Clinical Trials Database (30 Oct 2009)
- 23 Jun 2012 Additiona trial location (Sweden) added as reported by European Clinical Trials Database.
- 28 Apr 2012 Additional locations added as reported by European Clinical Trials Database record.